The 2014 American Association for Clinical Chemistry (AACC) awarded Sony DADC BioSciences and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC) with its Best Abstract of Interest to the Industry Division Award.
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays”, describes a process to integrate a novel silicon biosensor into a microfluidic chip which has the potential to enable customers to design highly cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than any commercially available solution.
The Industry Division Award is selected by a review committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the In-Vitro Diagnostic industry in management, regulatory affairs, or improved patient care through a new or improved medical device. This award was presented at the 2014 AACC Annual Meeting and Clinical Lab Expo, the world’s largest laboratory medicine exposition, and has been presented eight times since 2005.
The award-winning research combines Sony DADC BioSciences’ leading position in OEM manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It is aimed at overcoming a major hurdle for further development of POC devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
“Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management,” said Dr. Christoph Mauracher, Senior Vice President at Sony DADC BioSciences.
TSMC created the semiconductor Dedicated IC Foundry business model when it was founded in 1987. TSMC served over 440 customers and manufactured more than 8,600 products in 2013 for various applications covering a variety of computer, communications and consumer electronics market segments. Total capacity of the manufacturing facilities managed by TSMC, including subsidiaries and joint ventures, reached 16.4 million eight-inch equivalent wafers in 2013. TSMC operates three advanced 12-inch wafer GIGAFAB™ facilities (fab 12, 14 and 15), four eight-inch wafer fabs (fab 3, 5, 6, and 8), and one six-inch wafer fab (fab 2). TSMC also manages two eight-inch fabs at wholly owned subsidiaries: WaferTech in the United States and TSMC China Company Limited, In addition, TSMC obtains 8-inch wafer capacity from other companies in which the Company has an equity interest.
For more information, please visit http://www.tsmc.com
About Sony DADC BioSciences
Building on Sony DADC’s experience in high-precision optical disc manufacturing, Sony DADC’s BioSciences division partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts. Sony DADC’s global set-up comprises production sites, distribution hubs, digital & service facilities in 19 countries worldwide, including Japan, the US and Europe.